John Flygare
Head of Large Molecule & ADC Innovation Eli Lilly & Co.
Seminars
Wednesday 9th September 2026
Tumor Selectivity Strategies Across Multispecifics, TCEs, & ADCs: What Have we Learnt so Far?
11:40 am
- Engineering conditional activation through masking and pre-dosing in TCEs and ADCs
- Discussing dual-target and multispecific approaches
- Applying induced proximity to ADC specificity to substantially change the behaviour of an ADC
Wednesday 9th September 2026
Presentation Session One: Showcase Your Science
1:45 pm
Present your company’s slides by securing a 15-minute presentation slot in front of the attending audience, within this track.
Wednesday 9th September 2026
2025/26 Deal-Making Highlights: How Did They Happen?
4:40 pm
- Representing examples of successful deal-making and successful management of alliances to foster future deals, what are the learnings?
- Sharing how early-stage programs can successfully navigate the “show me data” barrier with pharma, and the activation barrier to licencing technologies between equal sized biotech
- Debating recent regulatory and emerging technology shifts, and how these will shape licensing deals for the discussed modalities
